A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication

European Journal of Vascular and Endovascular Surgery

Volumn 23, Issue 5, 2002, Pages 381-387

  McGrath, C ^a   Robb, R ^b   Lucas, A J ^a   Stewart, A H R ^a   Underwood, C L ^b   Horridge, J K ^a   Lamont, P M ^a   Smith, F C T ^a   Baird, R N ^a   Belch, J J F ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Immune modulation therapy; Intermittent claudication; Peripheral arterial occlusive disease

Indexed keywords

AGED; ANGINA PECTORIS; ARTICLE; BLOOD AUTOTRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUODENUM PERFORATION; FEMALE; HUMAN; IMMUNOMODULATION; INFLUENZA; INTERMITTENT CLAUDICATION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ULTRAVIOLET RADIATION; BIOASSAY; COMPARATIVE STUDY; FOLLOW UP; HOSPITALIZATION; IMMUNOLOGY; IMMUNOTHERAPY; PAIN; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; ARTERIAL OCCLUSIVE DISEASES; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; IMMUNOTHERAPY; INTERMITTENT CLAUDICATION; MALE; PAIN; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036583999     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1635     Document Type: Article

References (34)

1. SCHROLL M, MUNK O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurement in a population study of 60 year old men and women. J Chron Dis 1981; 34: 261-269.
2. MEIJER WT, HOES AW, RUTGERS D et al. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1997; 18: 185-192.
3. REGENSTEINER JG, STEINER JF, HIATT WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996; 23: 104-115.
4. HIATT WR, REGENSTEINER JG, HARGARTEN ME, WOLFEL EE, BRASS EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990; 81: 602-609.
5. HOUSLEY E. Treating claudication in five words. Br Med J (Clin Res Ed) 1988; 296: 1483-1484.
6. JONASON T, RINGQVIST I, OMAN-RYDBERG A. Home-training of patients with intermittent claudication. Scand J Rehabil Med 1981; 13: 137-141.
7. CLIFFORD PC, DAVIES PW, HAYNE JA, BAIRD RN. Intermittent claudication: is a supervised exercise class worth while? Br Med J 1980; 280: 1503-1505.
8. REGENSTEINER JG, MEYER TJ, KRUPSKI WC, CRANFORD LS, HIATT WR. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997; 48: 291-300.
9. BEEBE HG. Intermittent claudication: effective medical management of a common circulatory problem. Am J Cardiol 2001; 87: 14-18.
10. LEWIS DR, BULBULIA RA, MURPHY P et al. Vascular surgical intervention for complications of cardiovascular radiology: 13 years' experience in a single centre. Ann R Coll Surg Engl 1999; 81: 23-26.
11. DORMANDY JA, RUTHERFORD RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31: S1-S296.
12. BULMER J, BOLTON AE, POCKLEY AG. Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations. J Biol Regul Homeost Agents 1997; 11: 104-110.
13. COURTMAN DW, EDVINSSON L, EDVINSSON M et al. Vasocare™ therapy improves endothelial function in Watanabe rabbits and in humnas with advanced atherosclerosis. In: 73rd American Heart Association; 2000; New Orleans, U.S.A.; 2000.
14. BABAEI S, STEWART DJ, PICARD P, MONGE JC. Effects of Vasocare™ therapy on the initiation and progression of atherosclerosis. Atherosclerosis (in press) 2001.
15. FREED I, SHAHID S, WANG B et al. Role of transforming growth factor-beta-1 in the Th1/Th2 mechanisms of Vasogen's immune modulation therapy: Potential role in psorasis. In: 62nd Annual Meeting of the Society for Investigative Dermatology. 2001; Washington DC, U.S.A.; 2001.
16. SHIVJI GM, SUZUKI H, MANDEL AS, BOLTON AE, SAUDER DN. The effect of VAS972 on allergic contact hypersensitivity. J Cutan Med Surg 2000; 4: 132-137.
17. LIEBERMAN EH, UEHATA A, POLAK J et al. Flow mediated vasodilation is impaired in the brachial artery of patients with coronary artery disease or with diabetes mellitus (abstract). Clin Res 1993; 41: 217A.
18. VALENTINE RJ, GRAYBURN PA, EICHHORN EJ, MYERS SI, CLAGETT GP. Coronary artery disease is highly prevalent among patients with premature peripheral vascular disease. J Vasc Surg 1994; 19: 668-674.
19. ANDERSON TJ, GERHARD MD, MEREDITH IT et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75: 71B-74B.
20. TSAO PS, AOKI N, LEFER DJ, JOHNSSON GD, LEFER AM. Time course of endothelial dysfunction and myocardial injury during myocardial ischaemia and reperfusion in the cat. Circulation 1990; 82: 1402-1412.
21. TREMBLAY J, LUNES J, HAMET P. Vasocare therapy protects kidney from ischaemia/reperfusion-induced damage in the rat. Pathophysiol 1998; 5: 26.
22. COOKE ED, POCKLEY AG, TUCKER AT, KIRBY JDT, BOLTON AE. Treatment of severe Raynaud's syndrome by injection of autologous blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy. Inr Angiol 1997; 16: 250-254.
23. BABAEI S, COURTMAN DW, STEWART DJ. Vaso Care treatment inhibits progression of atherosclerosis in LDL receptor deficient mice. In: American College of Cardiology; 2000; Anaheim, California; 2000.
24. TISI PV, HULSE M, CHULAKADABBA A, GOSLING P, SHEARMAN CP. Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? Eur J Vasc Endovasc Surg 1997; 14: 344-350.
25. CREASY TS, MCMILLAN PJ, FLETCHER EW, COLLIN J, MORRIS PJ. Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial. Eur J Vasc Surg 1990; 4: 135-140.
26. LUNDGREN F, ZACHRISSON H, EMERY P et al. Leg exchange of amino acids during exercise in patients with arterial insufficiency. Clin Physiol 1988; 8: 227-241.
27. DAHLLOF AG, BJORNTORP P, HOLM J, SCHERSTEN T. Metabolic activity of skeletal muscle in patients with peripheral arterial insufficiency. Eur J Clin Invest 1974; 4: 9-15.
28. HOLM J, DAHLLOF AG, BJORNTORP P, SCHERSTEN T. Enzyme studies in muscles of patients with intermittent claudication. Effect of training. Scand J Clin Lab Invest Suppl 1973; 128: 201-205.
29. LARSEN OA, LASSEN NA. Effect of daily muscular exercise in patients with intermittent claudication. Lancet 1966; 2: 1093-1096.
30. BEEBE HG, DAWSON DL, CUTLER BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-2050.
31. MONEY SR, HERD JA, ISAACSOHN JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267-274; discussion 274-275.
32. DAWSON DL, CUTLER BS, MEISSNER MH, STRANDNESS DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686.
33. DAWSON DL. Comparative effects of cilostazol and other therapies for intermittent claudication. Am J Cardiol 2001; 87: 19D-27D.
34. GARDNER AW, POEHLMAN ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274: 975-980.